|
Search
Collections
Benchmarks
Upload document
DFF332
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
Org:
Novartis Pharmaceutical Corporation,